Dietary Supplement for Myopia Control

The purpose of this clinical trial is to investigate the changes in choroidal thickness and vasculature in myopic children following oral supplementation.

Inclusion Criteria: * Age 8-13 years * Cycloplegic spherical equivalent refraction (SER) of -0.50 D to -5.00 D with astigmatism of 2.5 D or less and best-corrected visual acuity (BCVA) of 0.0 logarithm or more in either eye * Anisometropia of 1.50 D or less * Intraocular pressure of 10 mmHg to 21 mmHg in both eyes * Willing to give written consent to participate in the study and accept random allocation in grouping Exclusion Criteria: * Ocular abnormalities leading to visual impairment * Severe physiological and psychological diseases affecting follow-up * Receiving previous myopia control treatment including but not limited to atropine therapy and orthokeratology in the past 3 months * Use of any other dietary supplements containing DHA/EPA, Lutein, or Astaxanthin in the past 3 months * Known history of allergy to any of the components of the dietary supplement or placebo, or history of an allergic reaction that required emergency treatment * Children who had other contraindications identified by the investigators that made them unsuitable for participation